Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903109533> ?p ?o ?g. }
- W2903109533 endingPage "736" @default.
- W2903109533 startingPage "729" @default.
- W2903109533 abstract "Although we currently have two, approved, disease-modifying drugs for the treatment of amyotrophic lateral sclerosis (ALS), we are in disperate need for more efficacious treatment. To aggressively test for newer therapies, we must develop reliable objective biomarkers to supplement clinical outcome measures. Many biomarker candidates have been actively and vigorously investigated. Among neurophysiological biomarkers, transcranial magnetic stimulation (TMS)-based biomarkers show potential in exploring disease mechanisms. Neuroimaging biomarkers have high specificity in diagnosing ALS but are an expensive endeavor and are not sensitive enough to detect changes over time of the disease. Among fluid-based biochemical biomarkers, creatinine (Crn) and uric acids (UA), which have been known for decades, may prove to be highly promising biomarkers that can predict disease progression. They can be easily tested in any clinical trials because the costs are minimal. Although known for some time, neurofilaments (NF), either phosphorylated-NF heavy subunit (pNFH) or NF light subunit (NFL), have emerged as new biomarkers using specific antibodies. They appear to be highly specific and sensitive in diagnosing ALS, yet they may be insensitive to assess changes in disease over time. These two NF biomarkers along with Crn and UA should be explored extensively in future clinical trials and any other clinical studies in ALS. Yet, we still need newer, more innovative, and reliable biomarkers for future ALS research. Fortunatley, aggressive investigations appear to be currently underway." @default.
- W2903109533 created "2018-12-11" @default.
- W2903109533 creator A5070593246 @default.
- W2903109533 creator A5089284579 @default.
- W2903109533 date "2018-01-01" @default.
- W2903109533 modified "2023-10-03" @default.
- W2903109533 title "A prognostic biomarker in amyotrophic lateral sclerosis" @default.
- W2903109533 cites W1480524493 @default.
- W2903109533 cites W1509365521 @default.
- W2903109533 cites W1830634249 @default.
- W2903109533 cites W1914037022 @default.
- W2903109533 cites W1970419934 @default.
- W2903109533 cites W1971782519 @default.
- W2903109533 cites W1979476115 @default.
- W2903109533 cites W1981295136 @default.
- W2903109533 cites W1985582661 @default.
- W2903109533 cites W1987385089 @default.
- W2903109533 cites W1993183966 @default.
- W2903109533 cites W1994776342 @default.
- W2903109533 cites W1995956993 @default.
- W2903109533 cites W1996111658 @default.
- W2903109533 cites W1997530390 @default.
- W2903109533 cites W2000411175 @default.
- W2903109533 cites W2005243883 @default.
- W2903109533 cites W2006507858 @default.
- W2903109533 cites W2006810171 @default.
- W2903109533 cites W2016652325 @default.
- W2903109533 cites W2017222498 @default.
- W2903109533 cites W2020279151 @default.
- W2903109533 cites W2026406888 @default.
- W2903109533 cites W2034454495 @default.
- W2903109533 cites W2039456249 @default.
- W2903109533 cites W2042033396 @default.
- W2903109533 cites W2043340127 @default.
- W2903109533 cites W2052542747 @default.
- W2903109533 cites W2053173388 @default.
- W2903109533 cites W2055538436 @default.
- W2903109533 cites W2056532188 @default.
- W2903109533 cites W2056627403 @default.
- W2903109533 cites W2059534047 @default.
- W2903109533 cites W2060163046 @default.
- W2903109533 cites W2065346979 @default.
- W2903109533 cites W2067856511 @default.
- W2903109533 cites W2071037100 @default.
- W2903109533 cites W2076314035 @default.
- W2903109533 cites W2077234258 @default.
- W2903109533 cites W2077612318 @default.
- W2903109533 cites W2080199849 @default.
- W2903109533 cites W2082397844 @default.
- W2903109533 cites W2089034809 @default.
- W2903109533 cites W2096936673 @default.
- W2903109533 cites W2100406540 @default.
- W2903109533 cites W2103795761 @default.
- W2903109533 cites W2109432431 @default.
- W2903109533 cites W2110184140 @default.
- W2903109533 cites W2115312929 @default.
- W2903109533 cites W2120338495 @default.
- W2903109533 cites W2124885415 @default.
- W2903109533 cites W2129239771 @default.
- W2903109533 cites W2131678573 @default.
- W2903109533 cites W2135000377 @default.
- W2903109533 cites W2136911505 @default.
- W2903109533 cites W2140370824 @default.
- W2903109533 cites W2141370217 @default.
- W2903109533 cites W2141763708 @default.
- W2903109533 cites W2149371897 @default.
- W2903109533 cites W2158562257 @default.
- W2903109533 cites W2162234541 @default.
- W2903109533 cites W2178618172 @default.
- W2903109533 cites W2200195488 @default.
- W2903109533 cites W2306559597 @default.
- W2903109533 cites W2460819002 @default.
- W2903109533 cites W2530101855 @default.
- W2903109533 cites W2547010172 @default.
- W2903109533 cites W2560731570 @default.
- W2903109533 cites W2590887570 @default.
- W2903109533 cites W2600914598 @default.
- W2903109533 cites W2604638361 @default.
- W2903109533 cites W2608240772 @default.
- W2903109533 cites W2612214304 @default.
- W2903109533 cites W2613485280 @default.
- W2903109533 cites W2620161024 @default.
- W2903109533 cites W2675950738 @default.
- W2903109533 cites W2755600438 @default.
- W2903109533 cites W2766294912 @default.
- W2903109533 cites W2766864364 @default.
- W2903109533 cites W2771354240 @default.
- W2903109533 cites W2775539932 @default.
- W2903109533 cites W2778854905 @default.
- W2903109533 cites W2784297687 @default.
- W2903109533 cites W2794716002 @default.
- W2903109533 cites W2800772770 @default.
- W2903109533 cites W2950589943 @default.
- W2903109533 doi "https://doi.org/10.5692/clinicalneurol.cn-001220" @default.
- W2903109533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30487362" @default.
- W2903109533 hasPublicationYear "2018" @default.
- W2903109533 type Work @default.
- W2903109533 sameAs 2903109533 @default.